Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease

Journal of Hypertension

Volumn 24, Issue SUPPL. 1, 2006, Pages

  Song, Joon Ho ^a   Cha, Seok Ho ^a   Hong, Seong Bin ^a   Kim, Dae Hyeok ^a  

^a Inha University School of Medicine   (South Korea)

Author keywords

Angiotensin II receptor blocker; Angiotensin converting enzyme inhibitor; Chronic kidney disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; RAMIPRIL; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG TISSUE LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY FIBROSIS; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; UREMIA; CHRONIC DISEASE; DRUG COMBINATION; KIDNEY DISEASE; PROTEINURIA; URINE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY DISEASES; PROTEINURIA; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33745565053     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000220414.99610.6b     Document Type: Review

References (35)

1. Lakkis J, Lu WX, Weir MR. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease. Curr Hypertens Rep 2003; 5:408-417.
2. Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000; 57:1803-1817.
3. Wolf G, Butzmann U, Wenzel UO. The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003; 93:3-13.
4. Huang XR, Chen WY, Truong LD, Lan HY. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003; 14:1738-1747.
5. Richard V, Hurel-Merle S, Scalbert E, Ferry G, Lallemand F, Bessou JP, Thuillez C. Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation 2001; 104:750-752.
6. Tikellis C, Johnston CI, Forbes JM, Burns WC, Burrell LM, Risvanis J, Cooper ME. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003; 41:392-397.
7. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension 2002; 39:129-134.
8. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005; 67:799-812.
9. Gesualdo L, Ranieri E, Monno R, Rossiello MR, Colucci M, Semeraro N, et al. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int 1999; 56:461-470.
10. Wolf G, Wenzel U, Assmann KJM, Stahl RA. Renal expression of aminopeptidase A in rats with two-kidney, one-clip hypertension. Nephrol Dial Transplant 2000; 15:935-942.
11. Weir MR, Henrich WL. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers. Curr Opin Nephrol Hypertens 2000; 9:403-411.
12. 2) angiotensin receptor. Proc Natl Acad Sci USA 1999; 96:6505-6510.
13. Komine N, Khang S, Wead LM, Blantz RC, Gabbai FB. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels. Am J Kidney Dis 2002;39:159-164.
14. Mervaala E, Dehmel B, Gross V, Lippoldt A, Bohlender J, Milia AF, et al. Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes. J Am Soc Nephrol 1999; 10:1669-1680.
15. Zoccali C, Valvo E, Russo D, Panichi V, Zuccalà A. Anti-proteinuric effect of losartan in patients with chronic renal diseases. Nephrol Dial Transplant 1997; 12:234-235.
16. Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M, Minutolo R. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33:851-856.
17. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM. Coadministration of losartan and enalapril exerts additive antiproteinuric effects in IgA nephropathy. Am J Kidney Dis 2001; 38:18-25.
18. Luno J, Barrio V, Goicoechea MA, Gonzalez C, De Vinuesa SG, Gomez F, et al. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies. Kidney Int 2002; 62 (suppl 82): S47-S52.
19. Campbell R, Sangalli F, Perticucci E, Aros C, Viscarra C, Perna A, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003; 63:1094-1103.
20. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, et al. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003; 139:244-252.
21. Nakao N, Seno H, Kasuga H, Toriyama T, Kawahara H, Fukagawa M. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 2003; 361:117-124.
22. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000; 321:1440-1444.
23. Wade VL, Gleason BL. Dual blockade of the renin-angiotensin system in diabetic nephropathy. Ann Pharmacother 2004; 38:1278-1282.
24. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy. Diabetes Care 2002; 25:95-100.
25. Jacobsen P, Andersen S, Rossing K, Hansen BV, Parving HH. Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrol Dial Transplant 2002; 17:1019-1024.
26. Jacobsen P, Andersen S, Jensen BR, Parving HH. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14:992-999.
27. Jacobsen P, Rossing K, Parving HH. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Curr Opin Nephrol Hypertens 2004; 13:319-324.
28. Reeves WB, Andreoli TE. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000; 97:7667-7669.
29. Wolf G, Mueller E, Stahl RA, Ziyadeh FN. Angiotensin II induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 1993; 92:1366-1372.
30. Kaneto H, Morrissey JJ, Klahr S. Increased expression of TGF-b mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993; 44:313-321.
31. Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, et al. Captopril-induced reduction of serum levels of transforming growth factorbeta correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999; 34:818-823.
32. Agarwal R, Siva S, Dunn SR, Sharma K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-b level. Am J Kidney Dis 2002; 39:486-492.
33. Song JH, Lee SW, Suh JH, Kim ES, Hong SB, Kim KA, Kim MJ. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 2003; 60:318-326.
34. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (suppl 1): S1-S266.
35. Bakris GL, Siomos M, Richardson D, Janssen I, Bolton WK, Hebert L, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000; 58:2084-2092.